October 14, 2019
As DNA sequencing becomes more common, providers face a dilemma over how much information they should reveal to their patients about their risks for untreatable conditions.
The number of dementia cases in the United States is "exploding," but the country has yet to come up with a plan to tackle the condition, a group of former U.S. surgeons general write for the Orlando Sentinel—and they offer ways the nation can address the crisis.
FDA earlier this month approved Gilead Science's Descovy to prevent HIV infection in men and transgender women, and some critics are taking issue with the agency's decision to approve the drug before Gilead tested it on a large scale in cisgender women.
FDA on Wednesday took another step toward advancing so-called "precision medicine" by finalizing guidance detailing how drugmakers developing cancer drugs can incorporate risk assessments from unapproved diagnostic tests into their clinical trial applications.
October 11, 2019
Providers in recent years have turned to vitamin C to treat sepsis based on limited evidence, and a study recently published in JAMA that sought to demonstrate whether the treatment is effective has left providers with no clear answers.
Only about one-third of pregnant women received both the influenza and tetanus, diphtheria, and acellular pertussis vaccines last year, even though CDC strongly recommends the vaccines for every pregnancy, according to CDC survey results published Tuesday.
American Health Line rounds up the latest health care news in the states.
October 10, 2019
The number of U.S. residents diagnosed with a sexually transmitted infection (STI) hit a record high in 2018, with almost 2.46 million reported cases of chlamydia, gonorrhea, syphilis, and other STIs, according to a CDC report released Tuesday.
A Philadelphia jury on Tuesday ordered New Jersey-based Johnson & Johnson (J&J) to pay $8 billion in punitive damages to a Maryland man who claimed J&J failed to properly warn patients and providers that its antipsychotic drug Risperdal could spur breast growth in boys.
GlaxoSmithKline on Tuesday announced that it is recalling the common heartburn drug Zantac in all markets as a "precaution," after FDA last week announced that it has detected "unacceptable" levels of a cancer-causing chemical in some samples of the drug—but the recall will not affect Zantac products sold in the United States.
Advisory Board. All rights reserved.